BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 27288955)

  • 1. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
    Maybury B; Cook G; Pratt G; Yong K; Ramasamy K
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1926-1937. PubMed ID: 27288955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.
    Gay F; Cavallo F; Palumbo A
    Drugs; 2015 Mar; 75(4):367-75. PubMed ID: 25764394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving role of stem cell transplantation in multiple myeloma.
    Harousseau JL; Moreau P
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem Cell Transplantation in Multiple Myeloma.
    Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
    Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
    Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final outcomes of escalated melphalan 280 mg/m
    Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
    Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
    Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
    Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
    Krishnan A; Vij R; Keller J; Dhakal B; Hari P
    Am Soc Clin Oncol Educ Book; 2016; 35():210-21. PubMed ID: 27249701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
    Malard F; Harousseau JL; Mohty M
    Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for patients with newly diagnosed multiple myeloma in 2015.
    Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
    Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.